Ceramides are lipids associated with atherosclerotic plaque formation, hypertension, insulin resistance, and obesity. Mayo Clinic Laboratories’ testing quantifies ceramides, providing an early indicator to help physicians predict heart disease in patients.
Dozens of studies involving more than 30,000 participants have confirmed the association between ceramides and cardiovascular risk, both in healthy populations (primary prevention) and those with known heart disease (secondary prevention).
The MI-HEART ceramide risk score measures four different ceramides and calculates a 12-point risk scale.
Patients with a ceramide risk score >7 have an 81% greater risk of a heart attack or stroke.
Over 7,500 patients have learned their MI-HEART ceramide risk score through Mayo Clinic Laboratories.
Ceramides Test menu
MI-Heart Ceramides, Plasma (Mayo ID: CERAM) is a blood test that quantifies plasma ceramides and estimates the risk for adverse cardiovascular events. Plasma ceramide concentrations are predictive of adverse cardiovascular events resulting from unstable atherosclerotic plaque. Ceramides are complex lipids that play a central role in cell membrane integrity, cellular stress response, inflammatory signaling, and apoptosis. Synthesis of ceramides from saturated fats and sphingosine occurs in all tissues. Metabolic dysfunction and dyslipidemia result in accumulation of ceramides in tissues not suited for lipid storage. Elevated concentrations of circulating ceramides are linked to a higher incidence of ischemic heart disease, myocardial infarction, stroke, and type 2 diabetes mellitus.
Three specific ceramides correlate with cardiovascular disease and insulin resistance: Cer16:0, Cer18:0, and Cer24:1. Individuals with elevated plasma ceramides are at higher risk of major adverse cardiovascular events even after adjusting for age, gender, smoking status, and serum biomarkers such as low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, and C-reactive protein (CRP). Studies have demonstrated increased therapeutic benefit among patients with elevated plasma ceramides. Ceramide concentrations are reduced by current cardiovascular therapies including a healthy diet, increased exercise, statins, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Take control of your heart health
MI-Heart Ceramides, Plasma (Mayo ID: CERAM) has the potential to save your life. It is a blood test that measures the risk of adverse cardiovascular events and quantifies plasma ceramides, which are clinically shown to be biomarkers of unstable atherosclerotic cardiovascular disease.
In short, it’s a better way to predict your risk of developing heart disease and your potential need for early intervention.
Fill out the form below and one of our specialists will be in touch.